3/18
02:07 pm
azn
Astrazeneca (AZN) had its "buy" rating reaffirmed by TD Cowen.
Low
Report
Astrazeneca (AZN) had its "buy" rating reaffirmed by TD Cowen.
3/15
05:59 pm
azn
AstraZeneca PLC (AZN) Secures US Priority Review For Candidate Breast Cancer Treatment [Yahoo! Finance]
Low
Report
AstraZeneca PLC (AZN) Secures US Priority Review For Candidate Breast Cancer Treatment [Yahoo! Finance]
3/12
06:11 pm
azn
Astrazeneca (AZN) is now covered by
Weiss Ratings. They set a "buy (b)" rating on the stock.
Low
Report
Astrazeneca (AZN) is now covered by
Weiss Ratings. They set a "buy (b)" rating on the stock.
3/12
09:24 am
azn
Low
Report
3/10
08:30 am
azn
AstraZeneca and Joshua Jackson partner to encourage fans to Get Body Checked Against Cancer
Low
Report
AstraZeneca and Joshua Jackson partner to encourage fans to Get Body Checked Against Cancer
3/9
07:00 am
azn
ENHERTU® (fam-trastuzumab deruxtecan-nxki) granted Priority Review in the US as post-neoadjuvant treatment for patients with HER2-positive early breast cancer
Medium
Report
ENHERTU® (fam-trastuzumab deruxtecan-nxki) granted Priority Review in the US as post-neoadjuvant treatment for patients with HER2-positive early breast cancer
2/20
07:00 am
azn
CALQUENCE® plus venetoclax approved in the US as first all-oral, fixed-duration combination for patients with chronic lymphocytic leukemia in the 1st-line setting
Low
Report
CALQUENCE® plus venetoclax approved in the US as first all-oral, fixed-duration combination for patients with chronic lymphocytic leukemia in the 1st-line setting
2/13
07:00 am
azn
Positive and clinically meaningful results from the Phase III KALOS and LOGOS trials for BREZTRI in patients with uncontrolled asthma published in The Lancet Respiratory Medicine
Neutral
Report
Positive and clinically meaningful results from the Phase III KALOS and LOGOS trials for BREZTRI in patients with uncontrolled asthma published in The Lancet Respiratory Medicine
2/11
09:00 am
azn
AstraZeneca awards $3.4 million for programs to improve access to healthcare for patients across the US
Low
Report
AstraZeneca awards $3.4 million for programs to improve access to healthcare for patients across the US
2/10
07:00 am
azn
AstraZeneca results: FY and Q4 2025
Low
Report
AstraZeneca results: FY and Q4 2025
2/6
03:11 pm
azn
AstraZeneca (NASDAQ:AZN) had its "sell" rating reaffirmed by analysts at Deutsche Bank Aktiengesellschaft.
Low
Report
AstraZeneca (NASDAQ:AZN) had its "sell" rating reaffirmed by analysts at Deutsche Bank Aktiengesellschaft.
2/4
01:40 pm
azn
Shell chief exec to become one of FTSE's best paid bosses [Yahoo! Finance]
Low
Report
Shell chief exec to become one of FTSE's best paid bosses [Yahoo! Finance]
2/4
12:40 pm
azn
Why pharma manufacturers are still investing in Europe [Yahoo! Finance]
Low
Report
Why pharma manufacturers are still investing in Europe [Yahoo! Finance]
2/4
08:13 am
azn
IonQ to Report Fourth Quarter and Full Year 2025 Financial Results on February 25, 2026 [Yahoo! Finance]
Low
Report
IonQ to Report Fourth Quarter and Full Year 2025 Financial Results on February 25, 2026 [Yahoo! Finance]
2/4
06:33 am
azn
AstraZeneca Oncology Advances Gain Momentum With New Cancer Approvals In Focus [Yahoo! Finance]
Low
Report
AstraZeneca Oncology Advances Gain Momentum With New Cancer Approvals In Focus [Yahoo! Finance]
2/3
07:55 pm
azn
Why Astrazeneca (AZN) Dipped More Than Broader Market Today [Yahoo! Finance]
Low
Report
Why Astrazeneca (AZN) Dipped More Than Broader Market Today [Yahoo! Finance]
2/3
07:22 pm
azn
Harbour BioMed Announces Positive Profit Alert for 2025 Annual Results [Yahoo! Finance]
Low
Report
Harbour BioMed Announces Positive Profit Alert for 2025 Annual Results [Yahoo! Finance]
2/3
12:02 pm
azn
Jim Cramer Says “I Like AstraZeneca Very Much” [Yahoo! Finance]
Low
Report
Jim Cramer Says “I Like AstraZeneca Very Much” [Yahoo! Finance]
2/3
10:56 am
azn
Walmart hits US$1 trillion in market value for the first time [BNN Bloomberg (Canada)]
Low
Report
Walmart hits US$1 trillion in market value for the first time [BNN Bloomberg (Canada)]
2/3
07:23 am
azn
DATROWAY® (datopotamab deruxtecan-dlnk) granted Priority Review in the US as 1st-line treatment for patients with metastatic triple-negative breast cancer who are not candidates for immunotherapy [Yahoo! Finance]
Low
Report
DATROWAY® (datopotamab deruxtecan-dlnk) granted Priority Review in the US as 1st-line treatment for patients with metastatic triple-negative breast cancer who are not candidates for immunotherapy [Yahoo! Finance]
2/3
07:00 am
azn
DATROWAY® (datopotamab deruxtecan-dlnk) granted Priority Review in the US as 1st-line treatment for patients with metastatic triple-negative breast cancer who are not candidates for immunotherapy
Low
Report
DATROWAY® (datopotamab deruxtecan-dlnk) granted Priority Review in the US as 1st-line treatment for patients with metastatic triple-negative breast cancer who are not candidates for immunotherapy
2/3
04:47 am
azn
AstraZeneca PLC (NASDAQ:AZN) Announces Strategic Collaboration Agreement With CSPC Pharmaceuticals [Yahoo! Finance]
Low
Report
AstraZeneca PLC (NASDAQ:AZN) Announces Strategic Collaboration Agreement With CSPC Pharmaceuticals [Yahoo! Finance]
2/3
02:53 am
azn
DATROWAY® Granted Priority Review in the U.S. as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy [Yahoo! Finance]
Low
Report
DATROWAY® Granted Priority Review in the U.S. as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy [Yahoo! Finance]
2/2
02:15 pm
azn
US and India reach trade deal, Astrazeneca shares move to NYSE [Yahoo! Finance]
Low
Report
US and India reach trade deal, Astrazeneca shares move to NYSE [Yahoo! Finance]
2/2
09:15 am
azn
NYSE Content Advisory: Pre-Market update + AstraZeneca Shares Begin Trading on NYSE in Record Transfer [Yahoo! Finance]
Low
Report
NYSE Content Advisory: Pre-Market update + AstraZeneca Shares Begin Trading on NYSE in Record Transfer [Yahoo! Finance]